Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Nurix Therapeutics, Inc. (NRIX)  
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30


Download
   
Exchange: N/A
Security Type: N/A
Shares Out: 47,040,000
Market Cap: N/A
Last Volume: 0 Avg Vol: 0
52 Week Range: $ - $
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  -
Guru Rank Value     :  -
Guru Occurances    :  -

 

                 
 
Company Profile   Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapies designed to modulate cellular protein levels as a treatment approach for cancer and other diseases. Co.'s Bruton's tyrosine kinase (BTK) degrader drug candidates, NX-2127 and NX-5948, are orally available chimeric targeting molecules for the treatment of relapsed or refractory B-cell malignancies and autoimmune indications. Co.'s drug candidate from its E3 ligase inhibitor portfolio, NX-1607, is an orally bioavailable Casitas B-lineage lymphoma proto-oncogene B inhibitor for immuno-oncology indications.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 15,218 35,430 43,924 56,372
Total Sell Value $172,193 $362,771 $427,193 $583,289
Total People Sold 3 3 3 4
Total Sell Transactions 5 10 16 32
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 166
  Page 6 of 7  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Ring Christine General Counsel   •       –      –    2021-04-12 4 AS $27.20 $32,640 D/D (1,200) 805     -
   Ring Christine General Counsel   •       –      –    2021-04-12 4 OE $1.86 $2,232 D/D 1,200 2,005     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-04-01 4 AS $31.55 $12,620 D/D (400) 13,804     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-04-01 4 OE $7.26 $2,904 D/D 400 14,204     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-03-25 4 OE $0.84 $3,637 D/D 4,330 4,330     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-03-16 4 AS $45.00 $36,000 D/D (800) 13,804     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-03-16 4 OE $7.26 $5,808 D/D 800 14,604     -
   Ring Christine General Counsel   •       –      –    2021-03-10 4 AS $39.44 $82,539 D/D (2,000) 805     -
   Ring Christine General Counsel   •       –      –    2021-03-10 4 OE $1.86 $3,720 D/D 2,000 2,805     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-03-08 4 AS $36.48 $277,678 D/D (7,500) 0     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-03-08 4 OE $0.84 $6,300 D/D 7,500 7,500     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-03-01 4 AS $35.95 $28,760 D/D (800) 13,804     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-03-01 4 OE $7.26 $5,808 D/D 800 14,604     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-24 4 AS $39.90 $1,413,218 D/D (35,419) 0     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-24 4 OE $1.20 $62,297 D/D 35,419 35,419     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-22 4 AS $39.93 $212,839 D/D (5,330) 0     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-22 4 OE $0.84 $5,886 D/D 5,330 5,330     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-02-18 4 AS $34.19 $532,352 D/D (15,000) 0     -
   Beaurang Pierre Chief Business Officer   •       –      –    2021-02-18 4 OE $0.84 $55,275 D/D 15,000 15,000     -
   Ring Christine General Counsel   •       –      –    2021-02-18 4 AS $34.48 $71,750 D/D (2,000) 0     -
   Ring Christine General Counsel   •       –      –    2021-02-18 4 OE $1.86 $3,720 D/D 2,000 2,000     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-02-18 4 AS $35.81 $29,018 D/D (800) 12,000     -
   Hansen Gwenn Chief Scientific Officer   •       –      –    2021-02-18 4 OE $7.26 $5,808 D/D 800 12,800     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-18 4 AS $34.24 $481,621 D/D (13,583) 0     -
   Van Houte Hans Chief Financial Officer   •       –      –    2021-02-18 4 OE $0.84 $11,410 D/D 13,583 13,583     -
  166 Records found
  1  2  3  4  5  6  7   
  Page 6 of 7
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us